BioAtla and BioDuro Team Up to Develop Two Biotech Drugs

BioAtla, a San Diego-China biotech, will collaborate with BioDuro to develop two therapeutic monoclonal antibodies in China. BioDuro is a Shanghai CRO, owned by PPD, that provides BioAtla with lab services. The two companies will develop the two mAbs through preclinical work and a Phase I trial before licensing each one to a China biopharma. The disease targets were not disclosed. More details.... Share this with colleagues: // //